XML 20 R8.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Retained earnings
Accumulated other comprehensive loss
Beginning balance (in shares) at Dec. 31, 2023   46,078,464      
Beginning balance at Dec. 31, 2023 $ 1,892,998 $ 461 $ 472,201 $ 1,491,956 $ (71,620)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 47,537     47,537  
Other comprehensive income (loss), net of tax expense (benefit) (6,715)       (6,715)
Issuance of restricted stock, net (in shares)   69,269      
Issuance of restricted stock, net (3,838)   (5,252) 1,414  
Issuance of shares under employee stock purchase plan (in shares)   92,589      
Issuance of shares under employee stock purchase plan 4,525 $ 1 4,524    
Repurchase and retirement of common stock (in shares)   (1,500,000)      
Repurchase and retirement of common stock (84,910) $ (15) (15,723) (69,172)  
Share-based compensation 20,472   20,472    
Other, net (182)   10 (192)  
Ending balance (in shares) at Jun. 30, 2024   44,740,322      
Ending balance at Jun. 30, 2024 1,869,887 $ 447 476,232 1,471,543 (78,335)
Beginning balance (in shares) at Mar. 31, 2024   46,134,708      
Beginning balance at Mar. 31, 2024 1,902,012 $ 461 475,926 1,503,838 (78,213)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 36,910     36,910  
Other comprehensive income (loss), net of tax expense (benefit) (122)       (122)
Issuance of restricted stock, net (in shares)   13,025      
Issuance of restricted stock, net 85   (100) 185  
Issuance of shares under employee stock purchase plan (in shares)   92,589      
Issuance of shares under employee stock purchase plan 4,525 $ 1 4,524    
Repurchase and retirement of common stock (in shares)   (1,500,000)      
Repurchase and retirement of common stock (84,910) $ (15) (15,723) (69,172)  
Share-based compensation 11,600   11,600    
Other, net (213)   5 (218)  
Ending balance (in shares) at Jun. 30, 2024   44,740,322      
Ending balance at Jun. 30, 2024 $ 1,869,887 $ 447 476,232 1,471,543 (78,335)
Beginning balance (in shares) at Dec. 31, 2024 42,848,339 42,848,339      
Beginning balance at Dec. 31, 2024 $ 1,810,882 $ 428 491,891 1,401,034 (82,471)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 50,582     50,582  
Other comprehensive income (loss), net of tax expense (benefit) 30,752       30,752
Issuance of restricted stock, net (in shares)   163,769      
Issuance of restricted stock, net (4,424) $ 2 (8,049) 3,623  
Issuance of shares under employee stock purchase plan (in shares)   133,956      
Issuance of shares under employee stock purchase plan 3,750 $ 1 3,749    
Repurchase and retirement of common stock (in shares) [1]   (1,978,007)      
Repurchase and retirement of common stock [1] (70,571) $ (19) (24,583) (45,969)  
Share-based compensation 21,479   21,479    
Other, net $ 209   11 198  
Ending balance (in shares) at Jun. 30, 2025 41,168,057 41,168,057      
Ending balance at Jun. 30, 2025 $ 1,842,659 $ 412 484,498 1,409,468 (51,719)
Beginning balance (in shares) at Mar. 31, 2025   42,230,734      
Beginning balance at Mar. 31, 2025 1,821,365 $ 422 485,008 1,406,715 (70,780)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 26,343     26,343  
Other comprehensive income (loss), net of tax expense (benefit) 19,061       19,061
Issuance of restricted stock, net (in shares)   31,374      
Issuance of restricted stock, net (121) $ 1 (217) 95  
Issuance of shares under employee stock purchase plan (in shares)   133,956      
Issuance of shares under employee stock purchase plan 3,750 $ 1 3,749    
Repurchase and retirement of common stock (in shares) [2]   (1,228,007)      
Repurchase and retirement of common stock [2] (39,668) $ (12) (15,890) (23,766)  
Share-based compensation 11,727   11,727    
Other, net $ 202   121 81  
Ending balance (in shares) at Jun. 30, 2025 41,168,057 41,168,057      
Ending balance at Jun. 30, 2025 $ 1,842,659 $ 412 $ 484,498 $ 1,409,468 $ (51,719)
[1] Includes 143,161 shares received in connection with sale of our minority equity ownership interest in OpenEvidence during the three months ended June 30, 2025.
[2] Includes 143,161 shares received in connection with sale of our minority equity ownership interest in OpenEvidence (formerly know as Xyla, Inc. (“Xyla”)) during the three months ended June 30, 2025.